Wei Gao

ORCID: 0000-0002-4088-3210 · 5 papers in corpus
preprint 2025
Diagnostic Pitfalls of Incarcerated Gravid Uterus: Report of Two Cases and Literature Review
·doi:10.21203/rs.3.rs-7601608/v1

Abstract Background : Incarcerated gravid uterus (IGU), which is characterized by entrapment of the retroverted uterus within the pelvis during the gestational period, is an uncommon condition but might potentially lead to serious mater…

other 2025
The association of activity patterns on female reproductive diseases: a prospective cohort study of UK biobank
BMC public health ·doi:10.1186/s12889-025-21576-z

OBJECTIVE: Little is known about the role of timing of physical activity in female reproductive disorders. These disorders include polycystic ovary syndrome (PCOS), heavy menstrual bleeding (HMB), endometriosis, infertility, and pregnancy-r…

article 2022
Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
British journal of clinical pharmacology ·doi:10.1111/bcp.15440

AIM: Elagolix, a gonadotropin-releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add-back therap…

peer-review 2020
Author response for "Estimating the effect of elagolix treatment for endometriosis on post‐menopausal bone outcomes: a model bridging registrational phase III trials to an older real‐world population"
·doi:10.1002/jbm4.10401/v2/response1
article 2020
Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population
JBMR plus ·doi:10.1002/jbm4.10401

ABSTRACT Elagolix, a gonadotrophin‐releasing hormone antagonist, is used in premenopausal women with endometriosis. There is a risk of bone loss with elagolix, but the long‐term effects of BMD loss later in life cannot be directly assessed …